Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

医学 美罗华 中性粒细胞减少症 内科学 弥漫性大B细胞淋巴瘤 切碎 临床终点 临床研究阶段 不利影响 肿瘤科 淋巴瘤 胃肠病学 免疫学 化疗 临床试验
作者
Eliza A. Hawkes,Geoffrey Chong,Charmaine Smith,Sze-Ting Lee,Leonid Churilov,Joseph McKendrick,William Renwick,Piers Blombery,Niles Nelson,Tineke Fancourt,Joanne Hawking,Wendi Lin,Andrew M. Scott,Allison Barraclough,Joel Wight,Andrew Grigg,Colm Keane,Chun Yew Fong,Kate Manos
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 43-44 被引量:10
标识
DOI:10.1182/blood-2020-136024
摘要

Background: Novel strategies are needed to improve upon the 60% cure rate of upfront R-CHOP in advanced DLBCL. Single-agent immune checkpoint inhibition (ICI) has limited efficacy in heavily pre-treated DLBCL (response rate Avelumab (Av) is an anti-PDL1 monoclonal antibody with antibody dependent cell cytotoxicity (ADCC) activity which acts synergistically with rituximab (R) in vitro. We report the results of a phase II single arm study assessing safety of 1st line sequential AvR induction, R-CHOP & Av maintenance for DLBCL. Methods: Patients aged ≥18 years, ECOG 0-2 with untreated stage II-IV DLBCL and no active autoimmune disease were treated with AvR induction x2 cycles q2-weekly (Av 10mg/kg IV + R 375mg/m2 IV), followed by R-CHOP21 x 6 cycles then Av 10mg/kg x 6 cycles q2-weekly if in complete metabolic response (CMR) post R-CHOP. The primary endpoint was the rate of grade 3/4 immune-related adverse events (irAE). Secondary endpoints included overall response rate (ORR), failure free survival (FFS), overall survival (OS) and overall toxicity. Response was determined centrally by PET-CT (Lugano 2014 criteria). CMR rates by PET-CT post AvR induction and post C2 R-CHOP were exploratory endpoints. Genomic analysis was performed including next generation sequencing (NGS) based sequence variant detection, copy number analysis and structural variant detection. Results: 28 pts were enrolled from Dec 2017 to Oct 2019. Key baseline characteristics included median age 54 yrs (range 20-79); stage III/IV disease 68%; elevated LDH 61%; IPI ≥2 25%. Histology included 21 DLBCL NOS (75%; 14 GCB, 7 non-GCB by Hans algorithm), 6 primary mediastinal B-cell lymphoma (PMBCL; 21%) and 1 EBV positive DLBCL (4%). The study met its pre-specified primary endpoint of G3/4 irAE ORR post R-CHOP was 89% (all CR) (Figure 1). The ORR to 2 cycles of induction AvR was 60%, including 6 CMR (21%) across all diagnostic/histologic subgroups (n=1 PMBCL, n=2 non-GCB DLBCL, n=3 GCB DLBCL; Figures 1 and 2). Six pts (21%) progressed during AvR induction (with 1 pt completing only 1 x AvR cycle); all subsequently responded to R-CHOP. With a median follow-up of 16 months, 1-year FFS was 76% and OS 89%. Treatment was discontinued early in 5 pts; 2 during R-CHOP due to progressive disease and 3 during Av maintenance (n=1 immune hepatitis; n=1 pulmonary embolism initially reported as pneumonitis; n=1 progressive disease). Alterations in the CD274/PDCDLG2 locus were identified by NGS in 3 of 27 evaluable pts (n=2 PMBCL, n=1 EBV+ DLBCL). Full genomic analysis to identify factors associated with response will be presented. Conclusion: Sequential AvR induction, R-CHOP and Av maintenance in pts with newly diagnosed DLBCL is feasible with a manageable toxicity profile and a high CR rate. Responses to AvR alone were higher than expected based on the relapsed/refractory population and may suggest superior efficacy of ICI in the frontline setting. These results support ongoing sequential studies of immune priming with PD1/PDL1 inhibition prior to R-CHOP in DLBCL. Acknowledgements: Merck KgA for avelumab plus funding. Tour de Cure Scott Canning Early Career Grant (E Hawkes) and Wilson Centre for Lymphoma Genomics for biomarker testing. Download : Download high-res image (168KB) Download : Download full-size image Disclosures Hawkes: Astra Zeneca: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity’s Board of Directors or advisory committees; Roche: Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Research Funding, Speakers Bureau; BMS celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen-Cilag: Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Speakers Bureau; Merck Sharpe D takeda: Speakers Bureau; Merck KgA: Research Funding. Chong: Merck Serono: Research Funding; Bristol-Myers Squibb: Research Funding; Hutchison Medipharma: Research Funding; Bayer: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Servier: Research Funding; Isofol: Research Funding. Blombery: Novartis: Consultancy; Janssen: Honoraria; Amgen: Consultancy; Invivoscribe: Honoraria. Barraclough: Roche: Other: Conference sponsorship. Keane: Celgene: Honoraria, Other: Travel; BMS: Research Funding; Roche: Honoraria, Other: Travel, Speakers Bureau; MSD Oncology: Honoraria, Other: Travel; Gilead: Honoraria, Other: Travel, Speakers Bureau. Fong: Pfizer: Honoraria; Astellas: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Novartis: Honoraria; AbbVie: Honoraria. Manos: Bristol-Myers Squibb: Other: Conference sponsorship. OffLabel Disclosure: Avelumab is an anti-PDL1 monoclonal antibody. Inhibition of the PD1/PDL1 pathway stimulates anti-tumour immunity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被专注的念烟采纳,获得10
刚刚
临猗下大雨完成签到,获得积分10
刚刚
小蘑菇的应助被专注的念烟采纳,获得10
刚刚
奋斗的大白菜完成签到,获得积分10
刚刚
yunwen完成签到,获得积分10
刚刚
斯文败类的应助被专注的念烟采纳,获得10
刚刚
研友_VZG7GZ的应助被专注的念烟采纳,获得10
刚刚
CipherSage的应助被直率的问薇采纳,获得10
1秒前
1秒前
共享精神的应助被专注的念烟采纳,获得10
1秒前
lili完成签到,获得积分10
1秒前
Eric完成签到,获得积分10
1秒前
JamesPei的应助被专注的念烟采纳,获得10
1秒前
所所的应助被专注的念烟采纳,获得10
1秒前
无花果的应助被2222采纳,获得30
1秒前
我是老大的应助被专注的念烟采纳,获得10
1秒前
完美世界的应助被专注的念烟采纳,获得10
1秒前
LL完成签到,获得积分10
2秒前
安琪完成签到,获得积分10
2秒前
2秒前
高兴巧克力完成签到,获得积分10
3秒前
3秒前
华无剑的应助被呆萌忆秋采纳,获得10
3秒前
小骨仙完成签到 ,获得积分10
3秒前
3秒前
顾建瑜完成签到,获得积分10
4秒前
4秒前
5秒前
朴实的灵萱完成签到 ,获得积分10
5秒前
顾建瑜发布了新的文献求助10
6秒前
哈哈完成签到,获得积分20
6秒前
小涵完成签到,获得积分10
6秒前
7秒前
今天不熬夜完成签到 ,获得积分10
7秒前
溜溜梅完成签到,获得积分10
7秒前
快乐小猫咪完成签到,获得积分20
7秒前
why完成签到,获得积分10
7秒前
吃火龙果不吐米米完成签到 ,获得积分10
7秒前
苦尽甘来完成签到,获得积分10
7秒前
水水发布了新的文献求助50
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173474
求助须知:如何正确求助?哪些是违规求助? 9565719
关于积分的说明 21781727
捐赠科研通 7767700
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476832